The natural course of lung function decline in asbestos exposed subjects with pleural plaques and asbestosis.
Aged
Asbestos
/ adverse effects
Asbestosis
/ epidemiology
Clinical Deterioration
Disease Progression
Female
Fibrosis
/ diagnostic imaging
Germany
/ epidemiology
Humans
Lung
/ physiopathology
Lung Diseases, Interstitial
/ epidemiology
Male
Middle Aged
Occupational Exposure
/ adverse effects
Phenotype
Pleural Diseases
/ etiology
Respiratory Function Tests
/ methods
Retrospective Studies
Risk Assessment
Tomography, X-Ray Computed
/ methods
Asbestosis
Forced vital capacity
Interstitial lung disease
Lung fibrosis
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
Historique:
received:
28
10
2018
revised:
10
06
2019
accepted:
11
06
2019
pubmed:
22
6
2019
medline:
5
8
2020
entrez:
22
6
2019
Statut:
ppublish
Résumé
While there is a good knowledge of the natural course of lung function in interstitial lung diseases (ILD) like idiopathic lung fibrosis (IPF), many ambiguities remain in patients with asbestosis. Therefore, we evaluated the change in lung function in asbestos exposed subjects with pleural plaques and asbestosis and analysed corresponding morphology of computer tomography of the thorax. 93 asbestos exposed subjects with pleural plaques and asbestosis were analysed retrospectively at the Klinikum Bergmannsheil of the Ruhr-University of Bochum. Parameters of lung function were obtained at least twice and annual changes of FVC, TLC and DLCOsb were calculated. In addition, we assessed the predominant pattern in high-resolution computer tomography of the thorax (HRCT) and differentiated three phenotypes: p (pleural) -type, f (fibrosis) -type and m (mixed) -type. FU data are available in 56/93 (60.2%) patients. The annual deterioration (Mean ± SEM) of FVC is -31.46 ± 17.34 ml, of TLC -55.55 ± 25.67 ml, of DLCOsb -0.38 ± 0.07 mmol/min/kPa and of DLCOva -0.05 ± 0.01 mmol/min/kPa/L. A categorical change of FVC > -100 ml was found in 12/56 (21.4%) and 18/56 (32.1%) patients showed an annual loss of TLC > -100 ml. The greatest annual decline of FVC was observed in patients with the fibrotic phenotype on HRCT (-76.76 ± 66.43 ml) and the mixed phenotype (-81.52 ± 24.79 ml), while the pleural phenotype was less affected (-10.52 ± 25.07 ml). More than 20% of our cohort have a progressive disease with an annual loss of FVC > -100 ml. Patients with the fibrotic-phenotype or mixed-phenotype on HRCT are particularly at risk.
Identifiants
pubmed: 31226624
pii: S0954-6111(19)30203-3
doi: 10.1016/j.rmed.2019.06.013
pii:
doi:
Substances chimiques
Asbestos
1332-21-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-85Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.